Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 3Multiple Myeloma 2Recurrence 1Ovarian Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 15avelumab 12Nivolumab 9atezolizumab 5Cyclophosphamide 5fludarabine 4Interleukin-2 4ALT-803 4durvalumab 3cemiplimab 3aldesleukin 3Ipilimumab 3domatinostat 2budigalimab 2Paclitaxel 2Docetaxel 2Bevacizumab 2zimberelimab 1venetoclax 1talimogene laherparepvec 1rovalpituzumab tesirine 1regorafenib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1epacadostat 1efineptakin alfa 1daromun 1bempegaldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Merkel Cell × lorvotuzumab mertansine × Clear all
NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ImmunoGen, Inc.

Phase 1 Completed
97 enrolled
DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡